How COVID Can Help Us Refocus On The How And Why Of Value Assessment
Our second post in the Health Affairs blog series explores how value assessment can bridge the gap between healthcare consumption and payment decisions. Mark Linthicum, Darius Lakdawalla, and Chuck Phelps discuss emerging methods to [...]
The Future Of Value Assessment In A Post-Pandemic United States
We begin our Health Affairs blog series with the Global Liver Institute’s Donna Cryer sharing insights on how the pandemic has altered our views about how we measure value and how it influences access [...]
Value Must Be Inclusive
Author: Rick Chapman, PhD, Chief Science Officer In the context of value assessment, what does patient representativeness mean? A new infographic from IVI, "Value assessment should serve diverse populations and the organizations that provide [...]
IVI/PAVE Research to be Presented at SMDM Annual Meeting
Results Will Inform IVI's Major Depressive Disorder Model Professor Susan dosReis, PhD and Associate Professor Julia Slejko, PhD of the Center for Patient Driven Values in Healthcare Evaluation (PAVE), University of Maryland School of [...]
PRESS RELEASE: IVI Opens Registration for Methods Summit to Drive Patient-Centered Value Assessment
National Quality Forum's Dana Gelb Safran will Keynote October 27th Event Alexandria, VA — September 30, 2021 — The Innovation and Value Initiative (IVI), an independent, nonprofit research organization dedicated to advancing patient-centric value assessment, today opened registration [...]
IVI MEMBER SPOTLIGHT: The Assistance Fund
Over the summer, we sat down with Stephanie Marshall, Director of Advocacy from The Assistance Fund to learn more about the organization and their priorities for the future of value assessment. [...]
In Memoriam: Samuel Nussbaum, MD
The staff and volunteer leaders of the Innovation and Value Initiative (IVI) mourn the passing of Samuel Nussbaum, MD, on September 23, 2021. Dr. Nussbaum chaired the IVI Board of Directors since 2019 and was [...]
IVI Drug Pricing Proposal Statement
Jennifer Bright, Executive Director, Innovation and Value Initiative, issued the following statement on Biden Administration and Congressional Democrats drug pricing proposals. "While exercising government levers to address drug pricing and pricing transparency are needed, the [...]
IVI MEMBER SPOTLIGHT: Arthritis Foundation
IVI had a chance to sit down with Anna Hyde, Director of Patient Advocacy at the Arthritis Foundation to discuss the organization's goals and how they are getting involved with value assessment. [...]
Supporting Equity in Value Assessment
Author: Rick Chapman, PhD, Chief Science Officer, IVI How do we ensure that the data and methods used for value assessment adequately account for the diversity of patients and the urgent need to correct [...]
What Distinguishes IVI’s Approach to Value Assessment?
Author: Rick Chapman, PhD, Chief Science Officer, IVI Policymakers continue to grapple with finding the right approaches to curtailing drug costs and improving health care. Organizations that conduct value and health technology assessment (HTA) [...]
Toward Equity in Value Assessment: Paths Forward
Author: Jennifer Bright, MPA, Executive Director, IVI "Poor value assessment hardwires inequity into health." - Michelle McMurry-Heath, MD, PhD; Biotechnology Innovation Organization - Session 1: Meaningful Action Toward Health Equity IVI's three-part series on health [...]